Workshop A: Defense Counsel Only War Room

Dec 9, 2019 8:30am - 12:00pm

Speakers

Richard Silbert
Vice President, Chief Legal Strategist
Purdue Pharma L.P.

Geoffrey M. Drake
Partner
King & Spalding LLP (Atlanta, GA)

Adam C. Bassing
Associate General Counsel, Legal Affairs
UCB, Inc. (Smyrna, GA)

Workshop C: Cost, Competency and Communication Working Group: Drug and Medical Device In-House Counsel Speak on “The Three C’s”

Dec 9, 2019 2:00pm - 5:30pm

Speakers

Howard Cyr
Assistant General Counsel – Global Litigation Counsel
Teleflex

Keyna Skeffington
Senior Vice President and General Counsel
LivaNova

Rachel Gallagher
Director, Legal Counsel
Teva Pharmaceutical

Kailee Goold
Senior Counsel
Cardinal Health

Workshop D: “Next Gen” Boot Camp: Training New Lawyers to Become Key Assets to the Future Products Liability Bar

Dec 9, 2019 2:00pm - 5:30pm

Speakers

Bradley Matta
Associate Litigation Counsel
Mylan

Gregory Jackson
Vice President, Litigation
Nuvasive

Sandra Di lorio
Litigation Counsel
Endo Pharmaceuticals

Day 1 - Tuesday, December 10, 2019

7:00
Breakfast and Registration
8:00
Co-Chairs’ Opening Remarks
8:15
Drug and Medical Device Year in Review: How the Most Influential Product Liability Decisions of the Last Year are Impacting Your Clients and Cases
9:15

Focus on the FDA

FDA KEYNOTE ADDRESS
9:45
Morning Coffee Break
10:00
FDA THINK TANK: Analyzing New FDA Guidance on Recalls, 510K Reform, Artificial Intelligence, and Real World Evidence
10:45

State of the Union on Preemption

In the Aftermath of Albrecht: Implications of the Supreme Court’s Ruling on Preemption for Pharmaceutical Products Liability Litigation
11:30
Determining When and How to Pursue Preemption Defenses for 510(k) and PMA Devices
12:15
Networking Lunch
Hosted by:
1:15

Focus on the MDL Paradigm

MDL CASE STUDY: Analyzing the Unique Nuances of Today’s Three Most Significant MDLs
2:15
Developing Techniques for Managing MDL Complexities: Obtaining Tools for Identifying, Controlling and Reducing Meritless Claims
3:15
Refreshment Break
Hosted by:
3:30
Breakout Sessions A
4:15
Breakout Session B
5:00
Breakout Sessions C
5:45
Conference Adjourns to Day Two
Cocktail Party Hosted by:

Day 2 - Wednesday, December 11, 2019

7:15
Continental Breakfast
Hosted by:
8:00
Opening Remarks and Recap of Day One
8:15
THE FEDERAL COURTS DIVIDED: Overcoming Challenges to Jurisdiction in the Continuing Aftermath of BMS
9:00
A VIEW FROM THE BENCH: Judicial Insights into Drug and Medical Device Products Liability Litigation
10:30
Morning Coffee Break
10:45

DIVERSITY & INCLUSION

Incorporating Diversity and Inclusion into Your Trial Team: An Honest Discussion of What’s Working, What’s Not and How We Can Do Better
11:30
Critical Insights from a FDA Expert Witness: Frank Lessons from a Decade of Pharmaceutical Litigation
12:00
Networking Lunch
1:00
New Technologies and AI: Predicting Risks and Liabilities Associated with 3D Printing, Digital Diagnostic Healthcare Apps and Surgical Robotics
2:15
An Interview with the Enforcers: Government Enforcement Priorities and Their Link to the Realm of Drug and Device Product Liability Litigation
3:30
Afternoon Refreshment Break
3:45

Audience Polling

ETHICS – INTERACTIVE ETHICS DRILLS: Overcoming Ethical Dilemmas in Drug and Medical Device Litigation
4:45
Main Conference Concludes

Day 1 - Tuesday, December 10, 2019

7:00
Breakfast and Registration
8:00
Co-Chairs’ Opening Remarks

Larissa A. Eustice
Senior Legal Counsel
Bayer

Matthew L. Stennes
Vice President, Chief Litigation & Investigations Counsel
Medtronic

8:15
Drug and Medical Device Year in Review: How the Most Influential Product Liability Decisions of the Last Year are Impacting Your Clients and Cases

Larissa A. Eustice
Senior Legal Counsel
Bayer

Matthew L. Stennes
Vice President, Chief Litigation & Investigations Counsel
Medtronic

Amy Todd Klug
Associate General Counsel, Litigation & Corporate Operations, Legal Affairs
Daiichi Sankyo, Inc.

Brennan Torregrossa
Senior Vice President, Head of Global Litigation
GSK

Moderator:

Lori G. Cohen
Co-Chair, Global Litigation Chair, Pharmaceutical, Medical Device & Health Care Litigation Group Chair, Trial Practice Group
Greenberg Traurig, LLP

Our esteemed in-house counsel panelists will engage in an interactive discussion of the most important case law developments of the past year and explore their real-life impact on drug and medical device litigation practice as well as their implications and influence on future decisions, trends and strategies in this arena. Points of discussion will include:

 

  • A survey of the year’s most significant and influential court decisions involving drug and medical device claims
  • Pending decisions that may have the most foreseeable future impact
  • How practitioners can update their practice and litigation strategies in response to the latest developments

9:15

Focus on the FDA

FDA KEYNOTE ADDRESS

Speaker TBD

9:45
Morning Coffee Break
10:00
FDA THINK TANK: Analyzing New FDA Guidance on Recalls, 510K Reform, Artificial Intelligence, and Real World Evidence

Join this think-tank of industry insiders as they discuss the latest guidances, initiatives and developments at FDA influencing the products liability sphere, including new pronouncements on voluntary recalls, 510K device approvals, Artificial Intelligence and the use of real-world data (RWD) to generate real-world evidence (RWE). This session will conclude with an interactive Q&A addressing how this activity will affect our approach to drug and
device litigation.

10:45

State of the Union on Preemption

In the Aftermath of Albrecht: Implications of the Supreme Court’s Ruling on Preemption for Pharmaceutical Products Liability Litigation

Ashley Garry
Litigation & Legal Compliance Counsel
Eli Lilly & Co.

Stephen E. Marshall
Partner
Venable LLP (Baltimore, MD)

Michelle M. Bufano
Partner
Patterson Belknap Webb & Tyler LLP (New York, NY)

Andrew L. Campbell
Partner
Faegre Baker Daniels LLP (Indianapolis, IN)

  • Implications of the Supreme Court’s ruling on life sciences products liability litigation
  • Aspects of Albrecht that will likely be the subject of future litigation
  • Potential application of Albrecht to future factual disputes encountered not only in the context of implied preemption, but of express preemption
  • Possible jurisprudential implications of the Supreme Court’s ruling

11:30
Determining When and How to Pursue Preemption Defenses for 510(k) and PMA Devices

Howard Cyr
Assistant General Counsel – Global Litigation Counsel
Teleflex

Gregory Ostfeld
Shareholder
Greenberg Traurig LLP (Chicago, IL)

John P. Lavelle Jr.
Partner
Morgan Lewis & Bockius LLP (Philadelphia, PA)

Paul J. Cosgrove
Partner
Ulmer & Berne LLP (Cincinnati, Ohio)

Despite the Supreme Court’s steady dismantling of Medtronic v. Lohr, medical device companies still face difficulty in establishing preemption for 510(k) devices. This panel will examine the latest 510 (k) preemption efforts and strategies for navigating preemption motions for PMA devices.

 

  • Exploring the latest efforts around achieving preemption for 510(k) devices
  • How the defense bar can leverage the recent Utah state court’s ruling in Kelsey v. Alcon in future litigation
  • Demonstrating device-specific preemption requirements
  • Positioning your case so as to effectively and successfully preserve the preemption issue for appeal in 510(k) cases
  • Developing proven strategies for pursuing preemption defenses for PMA devices

12:15
Networking Lunch
Hosted by:
1:15

Focus on the MDL Paradigm

MDL CASE STUDY: Analyzing the Unique Nuances of Today’s Three Most Significant MDLs

Julie M. Lewis
General Counsel & Corporate Secretary
Carestream Health

Douglas J. Moore
Member
Irwin Fritchie Urquhart & Moore LLC (New Orleans, LA)

This panel will examine three MDLs that the pharmaceutical and medical device industries are very closely watching — In Re: National Prescription Opiate Litigation (MDL No. 2804 (opioids), Johnson & Johnson Talcum Powder MDL 2738 (talc); and 3M Company Combat Arms Earplug MDL 2885 (3M combat ear plugs). The panelists will compare and contrast the unique elements of these MDLs, and provide insights on:

 

  • Each of their distinctive litigation challenges
  • Successful plaintiff tactics and defense strategies
  •  Notable judicial rulings and key takeaways

2:15
Developing Techniques for Managing MDL Complexities: Obtaining Tools for Identifying, Controlling and Reducing Meritless Claims

Aviva Wein
Assistant General Counsel, Products Liability
Johnson & Johnson

Lisa M. Dunkin
Senior Litigation Counsel
Zimmer Biomet

James F. Murdica
Partner
Barnes & Thornburg LLP (Chicago, IL)

Harley V. Ratliff
Partner
Shook Hardy & Bacon (Kansas City, MO)

Moderator:

James Stephen Bennett
Partner
Faegre Baker Daniels LLP (Fort Wayne, IN)

  • Examining various techniques for managing MDL complexities
  • Using social media and online investigation tools to identify and control meritless claims early on
  • Effectively utilizing screening orders, lone pine orders and lexecon waivers
  • Developing tactics for approaching negotiations with plaintiffs’ counsel throughout the MDL process
  • Devising strategies for managing remand of remaining cases after MDL settlement

3:15
Refreshment Break
Hosted by:
3:30
Breakout Sessions A

The Practice of Drug and Medical Device Litigation:
Strategies for Combatting the Complexities of Today’s Products Liability Landscape


Track 1
Combatting Extreme Jury Verdicts: Navigating Extraneous Factors That are Influencing Juror Findings

Andrew D. Kaplan
Partner
Crowell & Moring LLP (Washington, DC)

 

In the current political environment, the public’s distrust in big corporations, shorter attention spans and increased willingness to accept “alternative facts” are all leading to more instances of the extreme and seemingly vengeful jury verdicts. This panel will provide trial presentation strategies aimed at combatting this escalating and worrisome trend.

  • Framing your narrative to reach today’s jurors
  • Overcoming juror biases and predispositions
  • Decreasing risks of extreme verdicts
The Business of Drug and Medical Device Litigation:
Understanding the True Costs of the New Products Liability Environment


Track 2
Mitigating Challenges Created by Third-Party Litigation Funding (TPLF) in the Mass Tort Arena

Daniel Healey
Corporate Counsel
Pfizer Inc.

Barbara R. Binis
Partner
Reed Smith LLP

David F. Norden

Troutman Sanders LLP (Atlanta, GA)

 

This panel will examine the actions that drug and device companies can take to mitigate the challenges created by TPLF in the mass tort arena. Discussion points will include:

  • Challenges created by TPLF
  • Proactive measures that companies can take to push back on the effects of TPLF
  • Recent state law strides towards requiring disclosure of TPLF agreements in civil lawsuits

4:15
Breakout Session B

The Practice of Drug and Medical Device Litigation:
Strategies for Combatting the Complexities of Today’s Products Liability Landscape


Track 1
Mock Litigation Exercise: An “In The Trenches” Approach to Battling Reptile Theory

Jobina Jones-McDonnell
Senior Counsel, Litigation and Risk
Endo Pharmaceuticals

Robert K. (Bobby) Woo
Partner
King & Spalding LLP (Atlanta, GA)

Kenneth A. Murphy
Partner
Drinker Biddle & Reath LLP (Philadelphia, PA)

 

The Reptile “fear-based” approach is especially dangerous in drug and device product liability cases, given today’s negative public perception of life sciences companies. To help you develop effective strategies for combatting reptile strategy from the earliest phases of litigation, our panelists will engage in a mock corporate deposition and demonstrate first-hand tactics for:

  • Diffusing plaintiff counsel attempts to utilize reptile approach before it gains traction
  • Responding to plaintiff counsel questions aimed at rattling even the most seasoned corporate witnesses
  • Asking questions on redirect which combat reptile approach
  • Creating your own evidence to be used in negotiations for deposition designations
The Business of Drug and Medical Device Litigation:
Understanding the True Costs of the New Products Liability Environment


Track 2
Crisis Management Response Live: Managing Public Relations and Overcoming Negative Media Exposure Before and During a Trial

Richard S. Levick
Chairman & CEO
LEVICK (Washington, D.C.)

Richard Silbert
Vice President, Chief Legal Strategist
Purdue Pharma L.P.

Kristie Kuhl
Managing Partner, Health
Finn Partners (Fairfield, CT)

 

In this session, two PR experts, an in-house counsel and a law firm attorney will discuss steps for managing a PR crisis and diffusing negative media exposure. Topics of discussion will include:

  • Establishing a communications infrastructure
  • Building the crisis management team
  • Monitoring the online social channels
  • Involving members of the press
  • Tailoring responses to the specific medium
  • Communicating with those who treat the patients
  • Collaborating with the regulatory body charged with complying with standards set by the FDA
  • Tracking, monitoring and reassessing threats

5:00
Breakout Sessions C

The Practice of Drug and Medical Device Litigation:
Strategies for Combatting the Complexities of Today’s Products Liability Landscape


Track 1
Incorporating Innovative Thinking and Outside-the-Box Problem Solving Into Your Trial Strategy

Franklin T. Pyle III
Assistant General Counsel
Olympus Corporation of the Americas

Kailee Goold
Senior Counsel
Cardinal Health

 

  • Understanding the necessity for critical thinking and creativity in developing your trial strategy
  • Incorporating creative ways to approach a case which will help to avoid a long litigation path
  • Presenting new arguments to the court, or presenting old arguments in a new and innovative way
  • Engaging in outside-the-box problem solving when faced with litigation hurdles
The Business of Drug and Medical Device Litigation:
Understanding the True Costs of the New Products Liability Environment


Track 2
Evaluating and Controlling E-Discovery Costs and Minimizing the Impact of New Data Privacy Laws on Discovery Spend

Daniel Curto
Sr. Director, Litigation Counsel
Biogen

John Galvin
Partner
Fox Galvin, LLC

 

Moderator:

Colleen Casey Voshell
Senior Managing Director – Technology/Discovery
FTI Consulting (Philadelphia, PA)

 

On an annual basis, the approximate budget for discovery in the United States is $40 billion — and the majority of that discovery is comprised of electronically stored information (ESI). This is a tremendous corporate expenditure layered with complications from the latest data privacy laws, which are posing a new challenges. This panel will provide valuable insights on:

  • Accurately measuring and evaluating e-discovery spend
  • Identifying costs hidden within individual cases or dispersed among different departments
  • Strategies for managing e-discovery costs in-house vs. sending everything out to a third-party vendor or law firm
  • Identifying key areas where you can capture and reduce your spend
  • Assessing how recent data privacy laws such as GDPR and California’s data privacy regs are impacting e-discovery discovery spend

5:45
Conference Adjourns to Day Two
Cocktail Party Hosted by:

Day 2 - Wednesday, December 11, 2019

7:15
Continental Breakfast
Hosted by:
8:00
Opening Remarks and Recap of Day One
8:15
THE FEDERAL COURTS DIVIDED: Overcoming Challenges to Jurisdiction in the Continuing Aftermath of BMS

Donald LeGower
Senior Counsel, Litigation
Bristol-Myers Squibb

Adrienne Byard
Partner
Shook, Hardy & Bacon LLP (Kansas City, MO)

Daniel L. Ring
Partner
Mayer Brown LLP (Chicago, IL)

Cara Edwards
Partner
DLA Piper (New York, NY)

In the two years since the Supreme Court’s ruling on jurisdiction in BMS, the District Courts remain divided over its application. This panel will examine the latest rulings on jurisdiction, and address such hot button questions as:

 

  • When does mere registration to do business expose an out-of-state corporation to general personal jurisdiction?
  • Whether product-specific, as opposed to plaintiff-specific, in-state contacts can support specific jurisdiction over claims brought by out-of-state plaintiffs
  • Does personal jurisdiction allow for nationwide class actions, representing out-of-state absent class members, against out-of-state corporate defendants?
  • Whether “stream of commerce” specific personal jurisdiction, based entirely on third-party transfers of allegedly injurious products, exists where a defendant has not engaged in any in-state activity concerning those products

9:00
A VIEW FROM THE BENCH: Judicial Insights into Drug and Medical Device Products Liability Litigation

Honorable Karen K. Caldwell
Chief Judge
U.S. District Court, Eastern District of Kentucky Panel Judge, Judicial Panel on Multidistrict Litigation (JPML)

Honorable Patti B. Saris
Chief Judge
U.S. District Court, District of Massachusetts

Honorable Loretta A. Preska
Senior Judge
U.S. District Court, Southern District of New York

Honorable Claire C. Cecchi
Judge
U.S. District Court, District of New Jersey

Moderator:

Andrew T. Bayman
Partner
King & Spalding LLP (Atlanta, GA)

Hear from a panel of esteemed judges on what arguments the courts find most effective and persuasive when presiding over a drug or medical device products liability case. Gain valuable judicial insights on what works and
doesn’t work in jury instructions, voir dire and opening/closing statements, as well as examples of poor witness selection, inability to connect with a jury, and good vs. bad lawyering.

10:30
Morning Coffee Break
10:45

DIVERSITY & INCLUSION

Incorporating Diversity and Inclusion into Your Trial Team: An Honest Discussion of What’s Working, What’s Not and How We Can Do Better

Greg A. Dadika
Associate General Counsel, Litigation
Becton, Dickinson and Company

Shevon D.B. Rockett
Partner
Dorsey & Whitney LLP (New York, NY)

Many in-house legal departments have espoused a commitment to diversity and have made it clear that diversity matters when vetting and choosing law firms to represent them. However, implementing a truly diverse trial team can prove challenging. Join this panel for an honest discussion of specific ways that law firms and companies can effectuate diversity and inclusion together.

 

  • Implementing policies and practices that will truly effect change and promote a diverse workplace
  • Understanding what specific evidence of diversity companies are seeking from outside counsel
  • Best practices for evaluating a firm’s efforts in promoting diversity

11:30
Critical Insights from a FDA Expert Witness: Frank Lessons from a Decade of Pharmaceutical Litigation

Susan Allen MD, MPH

Regulatory and Compliance Consultant

Randall L. Christian
Partner
Bowman and Brooke LLP (Austin, TX)

Tune in for an interview with Dr. Susan Allen, a seasoned FDA expert witness with years of experience working on and testifying in drug litigation cases. Dr. Allen will share candid insights with a well-known pharmaceutical
trial lawyer on how to identify the right FDA expert for a case, things to do and to avoid when interacting with an expert witness, what a seasoned expert witness will be looking for in you and your team when deciding to
take on a case, and how best to work with and prepare an expert witness for each stage of litigation.

12:00
Networking Lunch
1:00
New Technologies and AI: Predicting Risks and Liabilities Associated with 3D Printing, Digital Diagnostic Healthcare Apps and Surgical Robotics

Patrick Lytle
Director, Associate General Counsel
Fitbit

Sheea Sybblis
Senior Counsel
Boehringer-Ingelheim

Mildred Segura
Partner
Reed Smith (Los Angeles, CA)

Every industry is being affected by advances in technology including artificial intelligence, robotics and the Internet of Things — and the medical and healthcare sectors are no exception. The progression of digital health
innovation, the growing market of IoT and BodyTech/wearable devices are likely to have a significant impact on the product liability regime. This panel will engage in a discussion of these technological advancements, including:

 

  • Prospective litigation and tort liability threats associated with the marketing and distribution of medical and health apps that may not perform as intended or advertised
  • Emerging trends in surgical robotics product liability litigation
  • Lessons learned from recent recalls of 3D printing devices
  • Theories of potential liability related to the design, development, functioning, maintaining and updating of these products

2:15
An Interview with the Enforcers: Government Enforcement Priorities and Their Link to the Realm of Drug and Device Product Liability Litigation

David M. Eskew
Chief, Health Care & Government Fraud Unit
U.S. Attorney’s Office, District of New Jersey

Jenni Peacock
Senior Assistant Attorney General, Consumer Protection Division
Office of the Tennessee Attorney General

Ross S. Goldstein
Senior Litigation Counsel Consumer Protection Branch
U.S. Department of Justice (Washington, D.C.)

Gregg Shapiro
Chief, Affirmative Civil Enforcement
U.S. Attorney’s Office, District of Massachusetts

David Hart
Assistant Attorney-in-Charge of the Health Fraud Unit/ Consumer Protection Section
Oregon Department of Justice

Paul Singer
Chief, Consumer Protection Division
Office of the Texas Attorney General

Moderator:

Wendy West Feinstein
Partner
Morgan, Lewis & Bockius LLP (Pittsburgh, PA)

Join our panel of esteemed government enforcers as they share pointed insights on:

 

  • Preparing for criminal and civil enforcement actions stemming from drug and device products liability
  • How they identify companies for investigations, and when and why they choose to prosecute
  • Best practices for responding to a government investigation
  • Practical considerations for in-house and law firm counsel when faced with DOJ or AG actions

3:30
Afternoon Refreshment Break
3:45

Audience Polling

ETHICS – INTERACTIVE ETHICS DRILLS: Overcoming Ethical Dilemmas in Drug and Medical Device Litigation

Michael R. Smith
Associate General Counsel
Olympus Corporation of the Americas

Adam Bassing

Adam C. Bassing
Associate General Counsel, Legal Affairs
UCB, Inc. (Smyrna, GA)

Test your ethical skills with a series of anonymous polling questions on sensitive, complex hypothetical scenarios. Discover how your approach to tackling ethical dilemmas in drug and medical device litigation compares to
your peers, and benefit from a practical discussion of the polling results and important takeaways for your practice.

4:45
Main Conference Concludes

Workshop A: Defense Counsel Only War Room

Dec 9, 2019 8:30am - 12:00pm

$600

Speakers

Richard Silbert
Vice President, Chief Legal Strategist
Purdue Pharma L.P.

Geoffrey M. Drake
Partner
King & Spalding LLP (Atlanta, GA)

Adam C. Bassing
Associate General Counsel, Legal Affairs
UCB, Inc. (Smyrna, GA)

What is it about?

Open to defense counsel only — Join your peers for a state-of-the-industry analysis and candid discussion about the latest and greatest in plaintiffs’ bar tactics, as well as lessons learned from 2019’s biggest defense victories. In-house and law firm defense counsel are encouraged to participate in this unique, interactive networking session that will set the stage for the topics discussed in depth throughout the event and provide you with valuable
takeaways about what your peers from around the country are seeing from the plaintiffs’ bar.

 

  • Analyzing select mass torts, bellwether trials and key state court proceedings (including state MDLs) from around the country: what tactics are plaintiffs’ attorneys using?
  • Assessing drugs or devices which may be ripe for products liability litigation in 2020 in light of adverse event reports, social media postings and attorney advertising
  • Developing strategies for successful motions to dismiss and other dispositive motions
  • Key players: identifying which plaintiff firms are currently driving litigation, as well as the frequently testifying experts to look out for
  • Deconstructing recent noteworthy jury verdicts: what language and themes are resonating with today’s jurors?
  • Devising effective tactics for winning cases in unfriendly jurisdictions
  • Identifying and effecting key settlement strategies

12:30 – 2:00
Workshop Luncheon: Available to Participants Attending Both Morning and Afternoon Workshop Sessions

Workshop B: FDA 101 For The Life Sciences Products Liability Litigator: Essential Training on Approvals, Labeling, Recalls, and More

Dec 9, 2019 8:30am - 12:00pm

$600

What is it about?

Products liability litigation concerning pharmaceutical products and medical devices often hinges on what happened during the FDA pre-approval, approval, or post-approval periods. This comprehensive pre-conference workshop will provide training on critical components of the FDA approval and post-approval periods. From new drug applications to 510Ks to labeling requirements to good manufacturing practices and post approval
concerns related to recalls and withdrawals, this workshop will provide you with the critical FDA regulatory foundation essential to the advancement of your products liability practice.

Points of discussion will include:

 

  • Examining the components of the FDA drug review and approval process that have the greatest impact on products liability cases
  • Understanding the pivotal role of the label in matters of preemption and defense strategies
  • Exploring the importance of clinical trials and findings
  • Comprehending the influence of cGMPs (Current Good Manufacturing Practices) in products liability litigation
  • Analyzing how adverse events reports and recalls play into the scope of a products liability action

Medical Devices

 

  • Determining premarket approvals
  • Exploring the 510(k)-clearance process

 


12:30 – 2:00
Workshop Luncheon: Available to Participants Attending Both Morning and Afternoon Workshop Sessions

Workshop C: Cost, Competency and Communication Working Group: Drug and Medical Device In-House Counsel Speak on “The Three C’s”

Dec 9, 2019 2:00pm - 5:30pm

$600

Speakers

Howard Cyr
Assistant General Counsel – Global Litigation Counsel
Teleflex

Keyna Skeffington
Senior Vice President and General Counsel
LivaNova

Rachel Gallagher
Director, Legal Counsel
Teva Pharmaceutical

Kailee Goold
Senior Counsel
Cardinal Health

What is it about?

Esteemed members of ACI’s Drug and Medical Device Litigation In-House Counsel Faculty will lead this new and comprehensive workshop. This unique, interactive discussion will provide exclusive, and intimate networking and benchmarking opportunities that will shed light on the expectations of in-house counsel from their law firm partners. It is also a vehicle for other in-house counsel to benchmark their current “3C’s” strategies with the workshop presenters.

 

Cost

 

  • Monitoring legal spend and balancing the budget
  • Establishing best practices for cost reduction to enhance predictability for cash flow purposes
  • Identifying processes to assist with budgeting, fee arrangements and billing
  • Examining the value of licensing deals and structures

Competency

 

  • Finding the right talent with time-proven strategies
  • Considerations in selecting outside counsel
  • Evaluating the appropriateness of work product
  •  Reconciling firm capabilities versus individual attorney reputation and ability

Communication

 

  • Communicating value and collaboration between corporate legal and outside counsel
  • Establishing the desired level of commitment, availability and responsiveness early-on in the relationship
  •  Succinctly focusing on shared, pragmatic business goals
  • Determining preferences for formality of correspondence and practical versus academic guidance

 

Workshop D: “Next Gen” Boot Camp: Training New Lawyers to Become Key Assets to the Future Products Liability Bar

Dec 9, 2019 2:00pm - 5:30pm

$600

Speakers

Bradley Matta
Associate Litigation Counsel
Mylan

Gregory Jackson
Vice President, Litigation
Nuvasive

Sandra Di lorio
Litigation Counsel
Endo Pharmaceuticals

What is it about?

In this interactive session, up-and-coming drug and medical device products liability attorneys will benefit from the career insights of established members of the defense bar. These senior members of the life sciences products liability bar will provide attendees with the nuanced information they have gained in the trenches of litigation and provide guidance on how new attorneys can excel and become rising stars in their practice. This workshop will provide the “next generation” of the life sciences defense products liability bar with valuable strategies for increasing their value to their clients and their firms, and for standing out amongst the crowd.

 

  • Understanding how junior lawyers can parlay their experience on a trial team to help increase trial experience and exposure, and stand out as someone to watch in the future
    • Maximizing your role on a junior lawyer discovery team
    • Showcasing research and writing skills as well as analytical capabilities and overall common sense
  • Developing strategies and best practices for reaching the mid-level management level
    • Establishing a plan to become a “rain maker” – devising your own business development plan
    • Understanding the importance of being perceived as a future leader who has the ability to be a team player
    • The art of never saying no to a project task
  • Identifying the goals of your 10-year plan and determining where you want your career path to lead
    • Partner?
    • In-house counsel?
    • Consultant?